Physician profile
Kate Mcelroy
NPI 1588954549
$3,643.86
in general payments reported to CMS, 2019-2025
26 companies · $966 in 2025
The $966 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $210 · 2022: $691 · 2023: $896 · 2024: $881 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,743.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $934.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $708.81 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.97 | 2022-2025 | Jardiance |
| Pfizer INC. | $236.34 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $227.67 | 2022-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Abbvie INC. | $206.06 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.22 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $163.31 | 2021-2025 | Farxiga, Breztri |
| Amgen INC. | $125.71 | 2023-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $115.98 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $64.34 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.46 | 2022 | |
| Abbott Laboratories | $60.37 | 2021-2025 | Amplatzer Talisman, Freestyle Libre 3 |
| Dexcom, INC. | $57.23 | 2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $55.35 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $47.52 | 2023-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Edwards Lifesciences Corporation | $23.72 | 2025 | Sapien 3 Ultra Resilia |
| Vanda Pharmaceuticals INC. | $21.29 | 2023 | Hetlioz |
| Corcept Therapeutics | $16.47 | 2023 | Korlym |
| Aimmune Therapeutics, INC. | $16.37 | 2025 | Vowst |
| Actelion Pharmaceuticals US, INC. | $16.19 | 2023 | Opsumit, Uptravi |
| Horizon Therapeutics Plc | $15.06 | 2023 | Krystexxa |
| Tris Pharma INC | $15.05 | 2023 | Dyanavel Xr |
| Exact Sciences Corporation | $14.79 | 2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $13.74 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Mcelroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.